Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
MLL-AF4 cooperates with PAF1 and FACT to drive high-density enhancer interactions in leukemia.
Crump NT, Smith AL, Godfrey L, Dopico-Fernandez AM, Denny N, Harman JR, Hamley JC, Jackson NE, Chahrour C, Riva S, Rice S, Kim J, Basrur V, Fermin D, Elenitoba-Johnson K, Roeder RG, Allis CD, Roberts I, Roy A, Geng H, Davies JOJ, Milne TA. Crump NT, et al. Among authors: smith al. Nat Commun. 2023 Aug 25;14(1):5208. doi: 10.1038/s41467-023-40981-9. Nat Commun. 2023. PMID: 37626123 Free PMC article.
Modelling acquired resistance to DOT1L inhibition exhibits the adaptive potential of KMT2A-rearranged acute lymphoblastic leukemia.
Schneider P, Crump NT, Arentsen-Peters STCJM, Smith AL, Hagelaar R, Adriaanse FRS, Bos RS, de Jong A, Nierkens S, Koopmans B, Milne TA, Pieters R, Stam RW. Schneider P, et al. Among authors: smith al. Exp Hematol Oncol. 2023 Sep 22;12(1):81. doi: 10.1186/s40164-023-00445-8. Exp Hematol Oncol. 2023. PMID: 37740239 Free PMC article.
A human genome editing-based MLL::AF4 ALL model recapitulates key cellular and molecular leukemogenic features.
Bueno C, Torres-Ruiz R, Velasco-Hernandez T, Molina O, Petazzi P, Martinez A, Rodriguez V, Vinyoles M, Cantilena S, Williams O, Vega-Garcia N, Rodriguez-Perales S, Segovia JC, Quintana-Bustamante O, Roy A, Meyer C, Marschalek R, Smith AL, Milne TA, Fraga MF, Tejedor JR, Menéndez P. Bueno C, et al. Among authors: smith al. Blood. 2023 Nov 16;142(20):1752-1756. doi: 10.1182/blood.2023020858. Blood. 2023. PMID: 37756522
Lower Urinary Tract Symptoms in US Women: Contemporary Prevalence Estimates from the RISE FOR HEALTH Study.
Sutcliffe S, Falke C, Fok CS, Griffith JW, Harlow BL, Kenton KA, Lewis CE, Low LK, Lowder JL, Lukacz ES, Markland AD, McGwin G, Meister MR, Mueller ER, Newman DK, Pakpahan R, Rickey LM, Rockwood T, Simon MA, Smith AR, Rudser KD, Smith AL. Sutcliffe S, et al. Among authors: smith al. J Urol. 2024 May 4:101097JU0000000000004009. doi: 10.1097/JU.0000000000004009. Online ahead of print. J Urol. 2024. PMID: 38703067
Novel spirocyclic dimer, SpiD3, targets chronic lymphocytic leukemia survival pathways with potent preclinical effects.
Eiken AP, Smith AL, Skupa SA, Schmitz E, Rana S, Singh S, Kumar S, Mallareddy JR, de Cubas AA, Krishna A, Kalluchi A, Rowley MJ, D'Angelo CR, Lunning MA, Bociek RG, Vose JM, Natarajan A, El-Gamal D. Eiken AP, et al. Among authors: smith al. Cancer Res Commun. 2024 Apr 30. doi: 10.1158/2767-9764.CRC-24-0071. Online ahead of print. Cancer Res Commun. 2024. PMID: 38687198 Free article.
Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations.
Hart NH, Nekhlyudov L, Smith TJ, Yee J, Fitch MI, Crawford GB, Koczwara B, Ashbury FD, Lustberg MB, Mollica M, Smith AL, Jefford M, Chino F, Zon R, Agar MR, Chan RJ. Hart NH, et al. Among authors: smith al. JCO Oncol Pract. 2024 Apr 29:OP2300716. doi: 10.1200/OP.23.00716. Online ahead of print. JCO Oncol Pract. 2024. PMID: 38684036
1,319 results